Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab vs placebo after pleurectomy/decortication in malignant pleural mesothelioma
2024-519286-21-00Phase 3Authorised
- Sponsor
- GOIRC
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pleural mesothelioma comparing Atezolizumab with Placebo (2 arms). Primary endpoint: Disease-free survival (DFS). Planned start Dec 2024; status: authorised.
02
Drugs
atezolizumab
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on 2024-519286-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519286-21-00.